Prostate Cancer

FDA grants fast track status for MLN2704

Published in Cancer Weekly, December 30th, 2003

Millennium Pharmaceuticals, Inc., (MLNM) announced that the U.S. Food and Drug Administration (FDA) has granted its investigational cancer therapy, MLN2704, fast track designation.

MLN2704 is currently being evaluated in a phase I/II clinical trial at Memorial Sloan-Kettering Cancer Center and New York-Presbyterian Hospital/Weill Cornell Medical Center for the treatment of patients with metastatic androgen-independent prostate cancer.

"We are pleased that the FDA has recognized the critical situation shared by men who suffer from hormone refractory prostate cancer," said David Schenkein, MD, vice president, clinical oncology development, Millennium....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-12-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry